H. Lundbeck 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Charl van Zyl

최고 경영자

DKK 39.6m

총 보상

CEO 급여 비율	6.8%
CEO 임기	1.2yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	3.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Charl van Zyl 의 보수는 H. Lundbeck 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	DKK 3b
Jun 30 2024	n/a	n/a	DKK 3b
Mar 31 2024	n/a	n/a	DKK 2b
Dec 31 2023	DKK 40m	DKK 3m	DKK 2b

보상 대 시장: Charl 의 총 보상 ($USD 5.59M )은 Austrian 시장( $USD 2.50M ).

보상과 수익: Charl 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Charl van Zyl (57 yo)

1.2yrs

테뉴어

DKK 39,600,000

보상

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

리더십 팀

이름	위치	테뉴어	보상	소유권
Charl van Zyl	President & CEO	1.2yrs	DKK 39.60m	데이터 없음
Joerg Hornstein	CFO & Executive VP of Corporate Functions	2.3yrs	DKK 10.90m	0.0023% € 129.8k
Lars Bang	Executive Vice President of Product Development & Supply	5.8yrs	DKK 10.10m	0.038% € 2.2m
Per Luthman	Executive Vice President of Research & Development	5.8yrs	DKK 11.30m	0.014% € 799.5k
Tarek Samad	Senior VP & Head of Research	3.5yrs	데이터 없음	데이터 없음
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	데이터 없음	데이터 없음
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	데이터 없음	데이터 없음
Dianne Holto	Executive Vice President of People & Culture	less than a year	데이터 없음	데이터 없음
Ole Chrintz	Senior Vice President of International Markets	no data	데이터 없음	데이터 없음
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.8yrs	데이터 없음	데이터 없음
Bjorn Mogensen	Senior Vice President of Group Finance	2.3yrs	데이터 없음	데이터 없음
Jose Molinuevo	VP & Head of Experimental Medicine	no data	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 관리: LUNB 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Lars Rasmussen	Independent Chairman	11.8yrs	DKK 1.70m	0.010% € 576.5k
Lene Skole-Sorensen	Deputy Chairman	9.8yrs	DKK 1.20m	0.0062% € 353.4k
Jeffrey Berkowitz	Independent Director	6.7yrs	DKK 1.20m	데이터 없음
Lars Holmqvist	Director	9.8yrs	DKK 600.00k	0.0076% € 432.4k
Jakob Riis	Director	1.7yrs	DKK 450.00k	0.0055% € 312.3k
Ilse Wenzel	Independent Director	3.7yrs	DKK 70.00k	데이터 없음
Santiago Arroyo	Independent Director	3.7yrs	DKK 1.00m	데이터 없음
Camilla Andersson	Employee Representative Director	2.7yrs	DKK 400.00k	0.00010% € 5.7k
Dorte Clausen	Employee Representative Director	2.7yrs	DKK 400.00k	0.00011% € 6.3k
Hossein Armandi	Employee Representative Director	2.7yrs	DKK 400.00k	데이터 없음
Lasse Skibsbye	Employee Representative Director	2.7yrs	DKK 400.00k	데이터 없음

3.7yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: LUNB 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.

H. Lundbeck 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

H. Lundbeck A/S Announces Management Appointments

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

Recent updates

Third quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.68 in 3Q 2023)

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Second quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.60 in 2Q 2023)

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

Dividend of kr.0.70 announced

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령